Condition category
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Contact information



Primary contact

Dr Siow Ming Lee


Contact details

Consultant Medical Oncologist
The Department of Oncology
University College London Hospitals
1st Floor Central
250 Euston Road
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after excision repair cross-complementation group 1 (ERCC1) protein stratification, in patients with advanced/metastatic non-small cell lung cancer (NSCLC)


ET Trial

Study hypothesis

The trial will have two main objectives:
1. To detect an improvement in survival for ERCC1 positive patients treated with a non-platinum chemotherapy compared to platinum-based treatment
2. To establish non-inferiority or improvement in survival for ERCC1 negative patients treated with a platinum-based chemotherapy compared to non-platinum treatment

Secondary objectives:
1. To examine progression-free survival, response rate and quality of life between the two treatment regimens, according to ERCC1 status
2. To investigate whether the treatment effect differs according to:
2.1. Histology (squamous versus non-squamous)
2.2. Gender (males versus females)
2.3. Performance status
3. To undertake a cost-effectiveness analysis based on all patients, and according to ERCC1 status

As of 22/02/2011 the anticipated end date for this trial has been updated from 30/11/2011 to 31/12/2014

Ethics approval

Charing Cross Research Ethics Committee, 24/09/2008, ref: 08/H0711/45

Study design

A multicentre, randomised, phase III trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Stage IIIb or IV non-small cell lung cancer (NSCLC)


Patients are randomised to one of two treatment arms:
Arm A: cisplatin/pemetrexed (cisplatin 75 mg/m2 over one hour/pemetrexed 500 mg/m2 over 10 minutes - intravenous [IV] administration)
Arm B: paclitaxel/pemetrexed (paclitaxel 175 mg/m2 over three hours/pemetrexed 500 mg/m2 over 10 minutes - IV administration)

Patients will receive up to six cycles of treatment; all patients are assessed with each cycle of chemotherapy. The first post-chemotherapy visit should be completed 3 - 4 weeks after last chemotherapy cycle. Assessments will then be monthly until one year from the date of first chemotherapy cycle, then two-monthly thereafter.

Intervention type



Phase III

Drug names

Pemetrexed, cisplatin, paclitaxel

Primary outcome measure

1. To detect an improvement in survival for ERCC1 positive patients treated with a non-platinum chemotherapy compared to platinum-based treatment
2. To establish non-inferiority or improvement in survival for ERCC1 negative patients treated with a platinum-based chemotherapy compared to non-platinum treatment

Secondary outcome measures

1. Progression-free survival and response rate using RECIST
2. Quality of life - European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ C30) with additional lung cancer questions (LC 13) and EuroQol EQ-5D
3. Cost-effectiveness analysis - assessing trial medication use, management of adverse events, if other anti-cancer treatments used, assessing hospital admission episodes (in-patient nights) and day case visits, community-based support (e.g. visits to and from GP or nurse; time in hospice)

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Histologically confirmed NSCLC
2. Have a tissue biopsy available for sending to the central laboratory to determine ERCC1 status
3. Presentation with stage IIIb (not amenable to curative treatment) or IV disease staging scans must be no more than 28 days prior to randomisation. Patients with relapsed NSCLC must not have received prior chemotherapy or biological therapy (previous surgery or radical radiotherapy allowed).
4. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST)
5. Either sex, at least 18 years of age
6. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
7. Estimated life expectancy of at least 8 weeks
8. Adequate bone marrow function as evidenced by the following (assessed within 14 days of starting treatment):
8.1. Absolute neutrophil count (ANC) equal or more than 1.5 x 10^9/L
8.2. Platelet count equal or more than 75 x10^9/L
8.3. Haemoglobin equal or more than 9 g/dL
9. Adequate liver function as evidenced by the following (assessed within 14 days of starting treatment):
9.1. Total bilirubin equal or less than 1.5 x upper limit of normal (ULN)
9.2. Aspartate transaminase (AST) equal or less than 3 x ULN or equal or less than 5 x ULN is acceptable with liver metastases
9.3. Alanine transaminase (ALT) equal or less than 3 x ULN
10. Adequate renal function as evidenced by the following (assessed within 14 days of starting treatment):
10.1. Glomerular filtration rate (GFR) greater than 50 ml/min as measured by ethylenediaminetetraacetic acid (EDTA), or
10.2. GFR greater than 60 ml/min as measured by the Cockcroft and Gault formula
11. Previous palliative radiotherapy to non-target metastatic lesions is allowed (not in the 28 days prior to randomisation)
12. Patients with stable brain metastases will be allowed to enrol. Stable brain metastases being defined as no progression of brain metastases 28 days after treatment as documented by a computed tomography (CT) scan/magnetic resonance image (MRI) of the brain. Patients with incidentally discovered asymptomatic brain metastases may be enrolled and treated with trial chemotherapy without prior brain irradiation if deemed feasible by the treating physician.
13. Signed informed consent form
14. Use of effective contraception during, and for 6 months after trial treatment by patients of reproductive potential and partners of reproductive potential. Patients who receive aprepitant (anti-emetic) must be willing to use an alternative or back-up method to hormonal contraceptives as aprepitant may reduce their efficacy.
15. Female patients with childbearing potential must have a negative serum pregnancy test prior to randomisation

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Cytologically or clinically diagnosed NSCLC
2. Evidence of significant medical condition or laboratory finding which, in the opinion of the treating physician or chief investigator, makes it undesirable for the patient to participate in the trial, e.g.:
2.1. Congestive heart failure
2.2. Myocardial infarction within 6 months
2.3. Significant neurological or psychiatric disorders that would impact trial participation
2.4. Infection requiring intravenous (I.V.) antibiotics
2.5. Tuberculosis with ongoing therapy at trial entry
2.6. Superior vena cava syndrome, except if controlled with radiation
2.7. Active peptic ulcer disease
2.8. Uncontrolled diabetes mellitus
2.9. Any contraindication to high dose corticosteroid therapy such as herpes simplex, herpes zoster, hepatitis, or other disease
3. Presence of uncontrolled brain or leptomeningeal metastases thought to require immediate radiotherapy
4. Presence of clinically significant third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to trial entry
5. Unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs)
6. Unable or unwilling to take vitamin B12 and folic acid
7. A history of prior malignant tumour, unless the patient has been without evidence of disease for at least 3 years or the tumour was a non-melanoma skin tumour or early cervical cancer
8. Pregnant or lactating women
9. Inability to comply with protocol or trial procedures

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

University College Hospital
235 Euston Road Fitzrovia
United Kingdom

Sponsor information


University College London (UK)

Sponsor details

Gower Street
United Kingdom

Sponsor type




Funder type


Funder name

Eli Lilly and Company

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype



United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a peer reviewed journal.

IPD Sharing plan:
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

Intention to publish date

Participant level data


Basic results (scientific)

Publication list

2016 results in

Publication citations

  1. Results

    Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A, Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET), J Clin Oncol, 2017, 35, 4, 402-411, doi: 10.1200/JCO.2016.68.1841.

Additional files

Editorial Notes

14/01/2019: Publication details added. 30/11/2016: The following changes have been made to the record: 1. The overall trial dates have been updated from 01/12/2008 - 31/12/2014 to 22/11/2007 - 31/12/2017 and the recruitment dates have been updated from 01/12/2008 - 31/12/2014 to 02/10/2009 - 24/07/2013. 2. The availability of participant level data, public title and ethics approval reference number have been added. 3. Publication reference added. 18/11/2016: No publications found in PubMed, verifying study status with principal investigator.